Ketotifen FumarateCAS# 34580-14-8 |
- PF-4981517
Catalog No.:BCC2270
CAS No.:1390637-82-7
- Abiraterone
Catalog No.:BCC2259
CAS No.:154229-19-3
- Avasimibe
Catalog No.:BCC2274
CAS No.:166518-60-1
- Alizarin
Catalog No.:BCN3479
CAS No.:72-48-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 34580-14-8 | SDF | Download SDF |
| PubChem ID | 5282408 | Appearance | Powder |
| Formula | C23H23NO5S | M.Wt | 425.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (235.02 mM) H2O : 16.67 mg/mL (39.18 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | (E)-but-2-enedioic acid;10-(1-methylpiperidin-4-ylidene)-5H-benzo[1,2]cyclohepta[3,4-b]thiophen-4-one | ||
| SMILES | CN1CCC(CC1)=C2c3ccccc3CC(=O)c4sccc24.OC(=O)C=CC(O)=O | ||
| Standard InChIKey | YNQQEYBLVYAWNX-WLHGVMLRSA-N | ||
| Standard InChI | InChI=1S/C19H19NOS.C4H4O4/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19;5-3(6)1-2-4(7)8/h2-5,8,11H,6-7,9-10,12H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | An H1 receptor antagonist. |
Ketotifen Fumarate Dilution Calculator
Ketotifen Fumarate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3502 mL | 11.7509 mL | 23.5018 mL | 47.0035 mL | 58.7544 mL |
| 5 mM | 0.47 mL | 2.3502 mL | 4.7004 mL | 9.4007 mL | 11.7509 mL |
| 10 mM | 0.235 mL | 1.1751 mL | 2.3502 mL | 4.7004 mL | 5.8754 mL |
| 50 mM | 0.047 mL | 0.235 mL | 0.47 mL | 0.9401 mL | 1.1751 mL |
| 100 mM | 0.0235 mL | 0.1175 mL | 0.235 mL | 0.47 mL | 0.5875 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ketotifen (fumarate) is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer, which is used to prevent asthma attacks.
- D-(+)-Mannose
Catalog No.:BCC8311
CAS No.:3458-28-4
- SF1670
Catalog No.:BCC5482
CAS No.:345630-40-2
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- Loperamide HCl
Catalog No.:BCC4380
CAS No.:34552-83-5
- Madecassoside
Catalog No.:BCN1012
CAS No.:34540-22-2
- 6,7-Dehydroferruginol
Catalog No.:BCN3218
CAS No.:34539-84-9
- Beta,beta-Dimethylacrylalkannin
Catalog No.:BCN2767
CAS No.:34539-65-6
- Arnicolide D
Catalog No.:BCN7975
CAS No.:34532-68-8
- Arnicolide C
Catalog No.:BCN7978
CAS No.:34532-67-7
- 1,3,6-Trihydroxy-2,5-dimethoxyxanthone
Catalog No.:BCN7216
CAS No.:345287-92-5
- Myricanol triacetate
Catalog No.:BCN5281
CAS No.:34509-52-9
- Pseudoephedrine Hydrochloride; Threo-Ephedrine Hydrochloride
Catalog No.:BCC8241
CAS No.:345-78-8
- Boc-Asp-OtBu
Catalog No.:BCC3073
CAS No.:34582-32-6
- SB 611812
Catalog No.:BCC6257
CAS No.:345892-71-9
- SUN-B 8155
Catalog No.:BCC7405
CAS No.:345893-91-6
- Amicarbalide
Catalog No.:BCC8117
CAS No.:3459-96-9
- MM 11253
Catalog No.:BCC7782
CAS No.:345952-44-5
- Wilfornine A
Catalog No.:BCN3099
CAS No.:345954-00-9
- AS601245
Catalog No.:BCC6464
CAS No.:345987-15-7
- 5-hydroxypyrazine-2-carboxylic acid
Catalog No.:BCC1311
CAS No.:34604-60-9
- Maltotetraose
Catalog No.:BCN6709
CAS No.:34612-38-9
- Maltopentaose
Catalog No.:BCN8421
CAS No.:34620-76-3
- Maltohexaose
Catalog No.:BCN6710
CAS No.:34620-77-4
- 2-Benzoyloxy-3-hydroxynortropane
Catalog No.:BCN1872
CAS No.:34622-25-8
Generic selection criteria for safety and patient benefit [V]: Comparing the pharmaceutical properties and patient usability of original and generic nasal spray containing ketotifen fumarate.[Pubmed:27210891]
Drug Discov Ther. 2016;10(2):88-92.
The pH, osmotic pressure (cryoscopy), viscosity, squeeze force, spray angle, and spraying frequency of nasal spray containing Ketotifen Fumarate (1 brand-name product and 8 generic products) were measured. Based on the results of pH measurement, all products were weakly acidic (4.0 to 5.1). For all products, the osmotic pressure ratio to physiological saline was approximately 1. The viscosity of various products ranged from approximately 1.0 to 1.5 mPa.s. The spray angle of drug solution differed among the products: minimum, 46 degrees (Sawai and Fusachol); and maximum, 68.7 degrees (Sekiton). In particular, TOA, Sawai, Fusachol, and TYK showed significantly smaller angles compared to Zaditen (brand-name product). Container properties varied among the products: minimum squeeze force, 19.0 N (Sekiton); and maximum squeeze force, 43.1 N (Sawai). Based on these results, although all the above products are identical in dosage form and active ingredient, the differences in pharmaceutical properties, such as container operations and drug-solution spraying/attachment, may markedly influence patients' subjective opinions.
Comparison of Different Nanosuspensions as Potential Ophthalmic Delivery Systems for Ketotifen Fumarate.[Pubmed:27766218]
Adv Pharm Bull. 2016 Sep;6(3):345-352.
Purpose: The objective of this study was to develop, characterize, and comparatively investigate the Ketotifen Fumarate (KF) nanosuspensions (NSS) to enhance the permeability of KF. Methods: In the present work, the NSP and NSE were prepared by double-emulsion solvent evaporation/nanoprecipitation methods with poly (D,Llactide-co-glycolide) and Eudragit RL100 polymers, respectively. The loading efficiency, particle size, and polydispersity index of prepared different NSs were evaluated with scanning electron microscopy (SEM), X-ray diffraction, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), and in vitro release and transcorneal permeation . NSs were also compared on the basis of particle size and polydispersity index. Results: Particle size, polydispersity index, and loading efficiency of NSP1 and NSE3 showed the best value (158 nm, 117 nm, 0.21, 0.43 and 43%, 95.23%, respectively). SEM showed spherical globules and DSC results showed the reduction in crystallinity. The NSE3 formulations demonstrated significantly (p<0.05) higher drug release rates than the NSP1 due to increases in the surface area. Comparative studies showed that NSE release and permeability are higher than NSP. Conclusion: It is concluded that both NSP and NSE provide a useful dosage form for the ocular drug delivery which can enhance the permeability of KF.
Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate.[Pubmed:27403262]
Iran J Basic Med Sci. 2016 May;19(5):550-60.
OBJECTIVES: Ketotifen Fumarate (KF) is a selective and noncompetitive histamine antagonist (H1-receptor) that is used topically in the treatment of allergic conditions of rhinitis and conjunctivitis. The aim of this study was to formulate and improve an ophthalmic delivery system of KF. Ocular nanoparticles were prepared with the objective of reducing the frequency of administration and obtaining controlled release to improve the anti-inflammatory drug delivery. MATERIALS AND METHODS: In the present study, ocular KF loaded Eudragit RL 100 nanoparticles were prepared using O/W solvent diffusion method. The nanoparticles were evaluated for particle size, entrapment efficiency, surface morphology, X-ray diffraction (XRD), Fourier transform spectroscopy (FTIR), and differential scanning calorimetry (DSC). In vitro release and permeation studies were also carried out on nanoparticles. RESULTS: An average size range of 182 to 314.30 nm in diameter was obtained and encapsulation efficiency up to 95.0% was observed for all the formulations. Drug release for all formulations after 24 hr was between 65.51% and 88.82% indicating effective controlled release property of KF. The mechanism of drug release for best formulation was found to be fickian diffusion mechanism. KF nanoparticles containing high polymer concentration (1:15) presented a faster drug release and a higher drug penetration; on the contrary, nanoparticles containing low polymer concentration (1:7.5) were able to give a more sustained release of the drug and thus a slower KF permeation through the cornea. CONCLUSION: The study revealed that KF NPs were capable of releasing the drug for a prolonged period of time and increasing the ocular bioavailability.
